Stromal disrupting effects of nab-paclitaxel in pancreatic cancer - Wikidata - wikimedia - TriplyDB

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

http://www.wikidata.org/entity/Q34654904

about

Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Molecular therapeutics in pancreas cancer Molecular Targeted Intervention for Pancreatic Cancer Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction Neoadjuvant therapy for pancreas cancer: past lessons and future therapies Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer New challenges in perioperative management of pancreatic cancer Metastatic pancreatic cancer: Is there a light at the end of the tunnel?A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment.Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.Microenvironmental regulation of therapeutic response in cancer Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenografic Tumour Model Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer.Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer.Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Personalising pancreas cancer treatment: When tissue is the issue.Fibroblast heterogeneity in the cancer wound.Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.Spread of tumor microenvironment contributes to colonic obstruction through subperitoneal fibroblast activation in colon cancer.New targeted therapies in pancreatic cancer.Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration Obesity and Cancer: An Angiogenic and Inflammatory Link.SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer.Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.Role of pancreatic stellate cells in chemoresistance in pancreatic cancer.nab-Paclitaxel for the treatment of pancreatic cancer.Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer.Inflammation and pancreatic cancer: disease promoter and new therapeutic target.

P2860

Q24627664-017FF1E1-B5BB-4A7D-923C-CBBEB9376CCF Q26751709-6D1ECCCA-887F-431A-AA2B-5794F84D35C7 Q26798453-6586F563-6D2D-4236-97DE-6580FD44F0FC Q26799714-B66C3B48-6C51-4ABF-8878-4DFEEDC85252 Q26801834-435968AF-F4DC-40E4-ACDD-7A7547A0893E Q27004292-E7DA6952-6709-493A-8C95-91BA50A088FC Q28069864-8A8B4FA2-91CD-4AEB-9E65-E0FD63B4FD70 Q28075540-56C5D8FC-0A39-426F-894E-B1C1E8945AFF Q28082422-CDF1C76F-4A7B-4CAB-AD8D-38009902C08C Q28082919-587E4245-BD4B-406F-828C-AC10FF524123 Q30357192-C9085920-FF02-40E2-83CA-15EFE7F34622 Q30362001-8333A1FA-3FFD-48ED-BE8A-E2290FDB29AC Q30388746-9D5B9D50-C1D7-45DD-98E4-CCDE93B4EEB0 Q33654609-60D15462-E0EC-4D5D-A466-07F587823E75 Q33665450-13359E25-68B2-498A-A99C-6CA09A0E2C41 Q33669055-14069B0E-47F3-4945-A071-553BE682DBAF Q33686177-A3C70165-EA61-447A-955F-990CAD57C25D Q33748302-864957B1-5661-4FB9-9F36-1C64256F8E31 Q33751263-A53758DB-ABE7-446E-8633-01F0DC4D57C3 Q33801384-D48BA836-8B19-40F7-9465-F9BAFD13CE59 Q33964324-C2057D08-C9CD-44D7-857C-C9FF578458D9 Q34067863-9EBE0DA0-C18D-4F38-8B40-E5890C063CDC Q34177065-72F6D376-C104-46C7-A169-6AE99AFEE6BF Q34403588-4AC9B563-91E0-41DD-BC5D-473C42FD0CD6 Q35538478-25F3D971-0EFD-4CF8-BA0D-624EB4058804 Q35651453-47BC7697-7362-4F09-9636-84CDFC9CCD67 Q36117713-91956296-2AF9-4D96-B1ED-8F8B949D0939 Q36214623-09C12BB8-EE30-4645-8CD2-182CA4A0AFC3 Q36621587-FD404636-E29C-4ED0-9E7D-73E47B375EC3 Q36759129-7D2F410A-B46E-4BAB-8E85-EFAA59400595 Q36917864-55B0163E-9F32-4BC0-8E46-88836F94D721 Q37029731-E8C38EED-1C27-4D47-B479-7EDDDB5ED416 Q37082778-1044366B-2FE2-4C7D-9ACA-423BE542B409 Q37461422-955F1314-7B9D-46C4-9579-01FA8D20238F Q37577579-650D0DB6-C6B8-4574-96D6-E2C9906FEA10 Q37697130-42162732-5DCB-40DB-A5A6-9DBFB0D5F000 Q37705462-A00D42B9-4C52-4D62-B36B-1FD7DCA7DC31 Q37714111-EDDBCC00-DE00-4213-B9B2-7232A9675623 Q38165930-9411A99E-A6B3-4C07-B5F6-1828C3F6A732 Q38167608-D8DA16B4-225E-4ABE-B7AB-45448F92F938

P2860

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

http://www.wikidata.org/entity/Q34654904

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@ast

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@en

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@nl

type

label

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@ast

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@en

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@nl

prefLabel

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@ast

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@en

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@nl

P1433

Q34654904-E207C238-6BBD-4865-8DCB-8C053B563D42

P1476

Q34654904-6E77140A-4752-46DD-9C03-47157F8FD901

P2093

Q34654904-14548B14-BDA2-4C7E-BB77-B460E3972D9B

Q34654904-1C0C91A6-79A6-4274-AC33-C68BC20ACFA8

Q34654904-1D175DF5-D642-4615-924F-FDD4147FD749

Q34654904-2A68969A-13DA-41A6-BC14-36B031CA87C4

Q34654904-3977B3C1-7B44-4A2C-8C76-683876B7D9F3

Q34654904-40D113B4-67B3-4D65-AD70-30045F678648

Q34654904-6AA245C0-109C-49F8-8BF8-1778CE80B6AF

Q34654904-79D0E12E-092F-41C4-BD42-3EC319ECB439

Q34654904-81BBF380-5580-4579-AD09-0F35863B3668

Q34654904-8ECD9A78-A9A3-441C-B3E4-DDFA2EF76929

P2860

Q34654904-275C46BD-4E04-45B4-BD57-B81315DFE0B5

Q34654904-3921F7D6-3873-446F-A720-0B36B2D998EB

Q34654904-3A8F5E6A-10B4-471D-A672-77C7CDD421FB

Q34654904-46B3815A-1A85-4191-9C5F-9DD1966C3293

Q34654904-5B88F2F4-65FB-4A44-85BF-7A6D788E3BB7

Q34654904-5DA16362-4BC6-464B-B4AA-9D4EE299944B

Q34654904-8980DB46-2073-4022-A498-BD62592C0236

Q34654904-A9BD2C19-6E1B-426D-96C0-23D862BB1FBB

Q34654904-AF5120B6-93B1-4BDB-BFBC-73952996925F

Q34654904-C5C45278-8759-46DD-9D91-E0A2A2C7E25F

P2888

Q34654904-1A4D0889-B138-498E-BEFC-DA9957918D61

P304

Q34654904-061943A4-5CF9-40F9-BB8F-E3765716B1ED

P31

Q34654904-9924AC11-089A-42CF-8DD8-12AB473B0B6A

P356

Q34654904-0771D37A-3D49-4E8B-AE46-FB78025E24B9

P407

Q34654904-862B5772-3C64-45C0-986F-96BB8AE7653C

P433

Q34654904-09000B9E-CCCC-4173-BB9E-3D852D1ED258

P478

Q34654904-52E53115-2FCA-4C29-AD3F-F5866ABFCD3B

P577

Q34654904-2595D593-46F5-4CDB-9333-89CD41A8F908

P5875

Q34654904-AD8347EB-4B47-431B-B033-913B5B5C4BD2

P6179

Q34654904-64A5DA50-1F2B-44A6-89E6-7422759FF887

P698

Q34654904-62ACEFD5-B07C-4ABD-99FE-924E7E718F8B

P932

Q34654904-3127C120-84A2-490B-BEFC-FBB26950BA37

P356

P1433

British Journal of Cancer

P1476

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

@en

P2093

A Cubillo

http://www.w3.org/2001/XMLSchema#string

C Guerra

http://www.w3.org/2001/XMLSchema#string

C Plaza

http://www.w3.org/2001/XMLSchema#string

D Megias

http://www.w3.org/2001/XMLSchema#string

E Garcia-Garcia

http://www.w3.org/2001/XMLSchema#string

E de Vicente

http://www.w3.org/2001/XMLSchema#string

F Lopez-Rios

http://www.w3.org/2001/XMLSchema#string

J Rodriguez-Pascual

http://www.w3.org/2001/XMLSchema#string

M Barbacid

http://www.w3.org/2001/XMLSchema#string

M Hidalgo

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

Pancreatic cancer

Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Tumor-stroma interactions in pancreatic ductal adenocarcinoma.

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies.

P2888

P304

926-933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.415

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

254268842

http://www.w3.org/2001/XMLSchema#string

P6179

1001588688

http://www.w3.org/2001/XMLSchema#string

P698

23907428

http://www.w3.org/2001/XMLSchema#string

P932

3749580

http://www.w3.org/2001/XMLSchema#string